Article Per Year (5 Year)
p-Index From 2020 - 2025
0.778
P-Index
This Author published in this journals
All Journal Farmaka Jurnal Farmasi Klinik Indonesia Pharmacology and Clinical Pharmacy Research
Suwantika, Auliya A.
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Chemistry Health Professions Immunology & microbiology Materials Science & Nanotechnology Medicine & Pharmacology Public Health

Published : 4 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 4 Documents
Search

 1 
Pemantauan Terapi Obat Pada Pasien Unstable Angina Pectoris dan Hypertensive Heart Disease (HHD) di Salah Satu Rumah Sakit di Bandung Wiseva, Karina Olga; Setiadi, Anggi; Suwantika, Auliya A.
Farmaka Vol 21, No 2 (2023): Farmaka (Juli)
Publisher : Fakultas Farmasi, Universitas Padjadjaran

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24198/farmaka.v21i2.46809

Abstract

ABSTRAKAngina pektoris merupakan manifestasi klinis dari Sindrom Koroner Akut (SKA) yang mengarah pada penyakit jantung koroner. Hypertensive Heart Disease (HHD) atau dikenal sebagai penyakit jantung hipertensi merupakan bentuk respon atas kejadian peningkatan tekanan darah berkepanjangan yang mengakibatkan berbagai perubahan pada struktur miokard. Pasien mengeluhkan nyeri ulu hati dan dada selama satu minggu. Pemantauan terapi obat dilakukan di salah satu Rumah Sakit di Kota Bandung terhadap pasien yang memiliki diagnosis utama Acute Coronary Syndrome (ACS). Terapi yang diberikan diantaranya infus NaCl 0,9%, clopidogrel, ISDN, injeksi pantoprazole, injeksi furosemide, sirup sukralfat, amlodipine, bisoprolol, atorvastatin, curcuma, fenofibrate, allopurinol, dan lansoprazole. Terdapat efek samping dari terapi obat yang diberikan, namun terapi telah sesuai dengan kondisi pasien. Setelah pemeberian terapi selama lima hari, gejala yang dirasakan oleh pasien membaik dan berkurang.Kata kunci: Angina Pektoris, Penyakit Jantung Hipertensi, Pemantauan Terapi Obat ABSTRACTAngina pectoris is a clinical manifestation of Acute Coronary Syndrome (ACS) which leads to coronary heart disease. Hypertensive Heart Disease (HHD) or known as hypertensive heart disease is a form of response to prolonged increases in blood pressure which results in various changes to the myocardial structure. The patient complained of heartburn and chest pain for one week. Monitoring of drug therapy is carried out in a hospital in the city of Bandung for patients who have a primary diagnosis of Acute Coronary Syndrome (ACS). The therapies given included 0.9% NaCl infusion, clopidogrel, ISDN, pantoprazole injection, furosemide injection, sucralfate syrup, amlodipine, bisoprolol, atorvastatin, curcuma, fenofibrate, allopurinol, and lansoprazole. There are side effects from the drug therapy given, but the therapy is in accordance with the patient's condition. After giving therapy for five days, the symptoms felt by the patient improved and decreased.Keywords: Angina Pectoris, Hypertensive Heart Disease, Monitoring Drug Therapy
A Narrative Review of the Case Reports of Routine Immunization Performance During a Pandemic COVID-19 Rahayuningsih, Nur; Suwantika, Auliya A.; Diantini, Ajeng; Sinuraya, Rano K.
Pharmacology and Clinical Pharmacy Research Vol 9, No 3 (2024)
Publisher : Universitas Padjadjaran, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.15416/pcpr.v9i3.59264

Abstract

Routine immunization is a program that must ensure adequate coverage as one preventive measure against the transmission of vaccine-preventable disease (VPD). Vaccines are the most cost-effective healthcare investment as it has been shown to prevent and reduce the incidence of disease, disability, and death from VPD, which is estimated to kill 2 – 3 million people each year. As of July 11, 2020, the COVID-19 pandemic has been deemed the worst public health emergency in the world, with over 12 million positive cases and 556,342 fatalities documented in 213 nations. The impact of the pandemic on routine immunization has resulted in higher morbidity and mortality from this VPD in countries with low coverage. This review article comprehensively describes routine immunization services and case reports of immunization performance during the COVID-19 pandemic.   
Economic Evaluations of Artificial Intelligence Implementation in Diabetic Retinopathy Screening Ahmad, Ahmad; Zakiyah, Neily; Suwantika, Auliya A.
Pharmacology and Clinical Pharmacy Research Vol 9, No 3 (2024)
Publisher : Universitas Padjadjaran, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.15416/pcpr.v9i3.60068

Abstract

Diabetic retinopathy (DR) is a common complication of diabetes that damages retinal blood vessels and can lead to vision impairment. The application of Artificial Intelligence (AI) in DR screening offers a promising alternative to conventional methods. However, further research is crucial to determine the cost-effectiveness of this intervention.This study systematically reviewed economic evaluations of AI interventions in DR screening using data from PubMed and ScienceDirect (2014–2023). Studies in various healthcare settings assessing cost-effectiveness outcomes, such as incremental cost-effectiveness ratio (ICER) and net monetary benefit, were included. The CHEERS (Consolidated Health Economic Evaluation Reporting Standards) checklist was used to assess the reporting quality of included studies.AI intervention can potentially provide accurate diagnoses by performing complex data analysis quickly and consistently. Despite initial higher costs, AI screening often led to higher quality-adjusted life years (QALYs) and improved healthcare resource allocation, particularly in underserved areas. From several perspectives, AI screening is cost-effective compared to manual screening, which has a lower ICER. Seven out of eight articles concluded that using AI for screening is cost-effective. However, challenges in generalizing AI models across diverse populations suggest a need for further validation to prevent diagnostic bias and ensure healthcare equity. Specifically, the hybrid use of manual screening with AI assistance is more cost-effective than the other comparison methods.AI can improve diagnoses like DR through quick data analysis and accuracy, but human guidance is still needed for algorithm development and decision-making. Combining AI with human involvement can lead to more cost-effective interventions.
Analisis Efektivitas Biaya Terapi Penunjang Ivabradine untuk Gagal Jantung di RSUP dr. Hasan Sadikin Bandung Diliwiyani, Soraya; Zakiyah, Neily; Suwantika, Auliya A.
Indonesian Journal of Clinical Pharmacy Vol 12, No 2 (2023)
Publisher : Universitas Padjadjaran

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.15416/ijcp.2023.12.2.119

Abstract

Penyakit kardiovaskular menjadi penyakit tidak menular nomor satu dengan angka kematian tertinggi. Terapi standar (standard of care/SOC) untuk gagal jantung saat ini berupa pemberian obat golongan beta bloker dan obat golongan angiotensin-converting enzyme inhibitors (ACEI) ataupun angiotensin receptor blocker (ARB). Biaya yang dibutuhkan untuk pengobatan sangat besar karena pasien gagal jantung dengan penurunan fraksi ejeksi (HFrEF) membutuhkan perawatan di rumah sakit yang lebih lama. Tujuan penelitian adalah untuk mengetahui analisis efektivitas biaya dari SOC+ivabradine dibandingkan dengan SOC pada terapi HFrEF di RSUP dr. Hasan Sadikin Bandung, serta untuk mengetahui faktor-faktor yang memiliki pengaruh pada nilai ICER pada pengobatan HFrEF. Penelitian dirancang observasionnal dengan desain studi cross-sectional. Perspektif yang digunakan pada penelitian ini adalah perspektif rumah sakit dan perspektif BPJS. Pengambilan data dilakukan dengan menggunakan dari rekam medis yang terdapat di RSUP dr. Hasan Sadikin Bandung. Periode pengambilan sampel, yaitu pasien HFrEF tahun 2017–2021. Data biaya meliputi total biaya medik (perspektif rumah sakit) dan tarif INA-CBG (perspektif BPJS). Efektivitas klinis yang diukur adalah penurunan nadi. Berdasarkan hasil dari penelitian ini, didapatkan total biaya kelompok SOC+ivabradine sebesar Rp34.540.643 (perspektif rumah sakit) dan Rp16.211.023 (perspektif BPJS). Total biaya kelompok SOC sebesar Rp31.188.699 (perspektif rumah sakit) dan Rp14.683.897 (perspektif BPJS). Efektivitas berupa penurunan nadi pada kelompok SOC+ivabradine dan SOC secara berturut-turut adalah 18,09 dan 16,50. Nilai ICER didapatkan Rp2.106.936 (perspektif rumah sakit) dan Rp959.908 (perspektif BPJS). Faktor yang paling berpengaruh pada nilai ICER adalah penurunan nadi diikuti oleh biaya rawat inap dan biaya tindakan. Terapi SOC+ivabradine membutuhkan biaya tambahan untuk mendapatkan efektivitas yang lebih baik.
Co-Authors Ahmad Ahmad Ajeng Diantini, Ajeng Diliwiyani, Soraya Nur Rahayuningsih, Nur Setiadi, Anggi Sinuraya, Rano K. Wiseva, Karina Olga Zakiyah, Neily